What’s the Value of a Cancer Cure?

By Cyndy Nayer and Leonard Kish  When CMS approved Solvadi, Gilead’s $84,000 drug for hepatitis C, the stakes were raised in drug price wars.  Two opposing forces, one, a financial push toward lower costs came up against an opposing force of public sentiment. The FDA’s goal of getting 90% of patients moved from costly branded […]
Source: The Health Care Blog - Category: Consumer Health News Tags: THCB Cirrhosis CMS FDA Hepatitis B Hepatitis C HIV PhRMA Solvadi Value-Based Medicine value-driven pharmaceuticals Source Type: blogs